AI assistant
Immunome Inc. — Director's Dealing 2020
Oct 2, 2020
32238_dirs_2020-10-01_bd2e54bf-da37-4a93-a1ad-388cd2753bee.zip
Director's Dealing
Open in viewerOpens in your device viewer
SEC Form 3 — Initial Statement of Beneficial Ownership
Issuer: Immunome Inc. (IMNM)
CIK: 0001472012
Period of Report: 2020-10-01
Reporting Person: LAMATTINA JOHN L (Director)
Holdings (Derivative)
| Security | Exercise Price | Expiration | Underlying | Shares | Ownership |
|---|---|---|---|---|---|
| Series A Convertible Preferred Stock | $ | Common Stock (46388) | Indirect | ||
| Warrant (right to buy) | $9.00 | 2023-06-02 | Series A Convertible Preferred Stock (11111) | Indirect | |
| Stock Option (right to buy) | $0.36 | 2027-12-05 | Common Stock (23933) | Direct |
Footnotes
F1: Each share of Series A Preferred Convertible Stock is convertible at any time at the option of the holder, without payment of additional consideration, into Common Stock, on a one-for-one basis, has no expiration date and will automatically convert into shares of Common Stock upon the closing of the Issuer's initial public offering.
F2: The shares are held by John LaMattina Revocable Trust (the "Trust"). The Reporting Person is the trustee of the Trust and has voting and investment power with respect to shares held by the Trust.
F3: Immediately exercisable.
F4: Fully vested.